Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$2.04B+112.74%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jose Ignacio Abia Buenache
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 25,258
- Beta
- 1.19
- Country
- ES
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.12
Financials
Revenue
$2.04B+112.7%Net Income
$189.00M+50.9%EBITDA
$545.00M+92.9%Free Cash Flow
$283.00MEPS (diluted)
$0.28+55.6%Shares Outstanding (diluted)
680.58M-2.2%Operating Expenses
$388.00MCash & Debt
$486.00MReturn of Capital
$60.00MRevenue by Segment (annual)
$7.52BDividend per Share
$0.17Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.23B | $386.13M | $0.57 |
| 2024 | $7.21B | $156.92M | $0.23 |
| 2023 | $6.59B | $42.32M | $0.09 |
| 2022 | $6.06B | $185.03M | $0.31 |
| 2021 | $4.93B | $188.73M | $0.27 |
| 2020 | $5.34B | $618.55M | $0.73 |
| 2019 | $5.10B | $625.15M | $0.95 |
| 2018 | $4.49B | $596.64M | $0.87 |
| 2017 | $4.32B | $662.70M | $0.97 |
| 2016 | $4.05B | $545.46M | $0.80 |
| 2015 | $3.93B | $532.14M | $0.78 |
| 2014 | $3.36B | $470.25M | $0.69 |
| 2013 | $2.74B | $345.55M | $0.51 |
| 2012 | $2.62B | $256.69M | $0.38 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GRFS's reported EPS growth of 3.2% a year over 13 years.
- EPS in 5 years
- $0.66
- Implied price
- $9.30
- Return from $8.15
- 2.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.62 — -43.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -6.8% | -13.3% | -10.1% | -7.3% | -4.8% | -2.5% |
| -1.8% | -8.7% | -5.3% | -2.3% | 0.3% | 2.7% |
| 3.2% | -4.0% | -0.4% | 2.7% | 5.4% | 8.0% |
| 8.2% | 0.6% | 4.4% | 7.6% | 10.6% | 13.2% |
| 13.2% | 5.3% | 9.2% | 12.6% | 15.7% | 18.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60+11.11%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·19d ago·Positive
Grifols: Plasma, Profits, And Recovery Gathering Momentum Grifols remains a speculative 'BUY' with a €20/share price target, offering over 20% annual upside if growth continues. GIKLY has delivered strong 3Q26 results: revenue above €2B quarterly, EBITDA up 10%, net profit up 28%, and leverage now below 4x. Strategic expansion into Egypt is expected to diversify plasma sourcing, reduce costs, and support margin improvement through geographic diversification.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
Grifols Q3 Earnings Call Highlights Grifols NASDAQ: GRFS reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financial targets despite continued weakness in China's albumin market.
View source ↗ - Newszacks.com·59d ago·Negative
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsreuters.com·59d ago·Positive
Grifols says Canada plasma license suspension has no impact Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at its Taylor Avenue facility in Winnipeg had no impact on operations.
View source ↗ - Newsseekingalpha.com·67d ago·Neutral
…better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.
View source ↗ - Newszacks.com·75d ago·Neutral
GRFS or SDZNY: Which Is the Better Value Stock Right Now? Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $0.33 per share
Typical surprise -7.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$0.34 vs $0.32beat
- Tue, Jul 28$0.25 vs $0.27miss
- Thu, May 7$0.17 vs $0.16beat
- Thu, Feb 26$0.29 vs $0.29miss
- Tue, Nov 4$0.21 vs $0.24miss
- Tue, Jul 29$0.19 vs $0.23miss
Estimates and results for GRFS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (17d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Dec 23, 2019 (42d later)Sell$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
